Bristol-Myers Squibb
BMY
60.80
+0.23
+0.38%
Bristol-Myers Squibb
US · BMY
#158 by market cap
Listed 1970
60.80
+0.23
+0.38%
Live - 5344 symbols - heartbeat 441s ago
· 2026-10-16 11:00
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 7 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 83.16% -0.22pp
- Institutions
- 2,897 -7
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund68.63%
Public Company3.88%
Hedge Fund2.87%
Government Pension Fund2.63%
Private Company2.13%
Sovereign Wealth Fund1.90%
Insurance Company0.35%
Family Office/Trust0.30%
VC/PE Fund0.17%
Corporate Pension Plan0.15%
Other17.15%
Top holders as of 2026-06-30
BlackRock
8.83% · 180.38M sh
Vanguard Capital Management, LLC
7.09% · 144.81M sh
State Street Global Advisors
5.01% · 102.41M sh
Charles Schwab Investment Management
3.31% · 67.60M sh
J.P. Morgan Asset Management, Inc.
2.89% · 59.10M sh
Other
72.86%
Geode Capital Management, LLC
2.76% · 56.44M sh
Vanguard Portfolio Management, LLC
2.29% · 46.87M sh
Norges Bank Investment Management
1.80% · 36.87M sh
T. Rowe Price Group, Inc.
1.55% · 31.73M sh
UBS Asset Management
1.55% · 31.72M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Sandra Leung | Executive Vice President | 0.02% |
| David Elkins | Chief Financial Officer | 0.01% |
| Christopher Boerner | Chief Operating Officer | 0.01% |
| Theodore Samuels | Lead Independent Director | 0.00% |
| Julia Haller | Independent Director | 0.00% |
| Samit Hirawat | Executive VP & Chief Medical Officer of Drug Development | 0.00% |
| Greg Meyers | Executive VP and Chief Digital & Technology Officer | 0.00% |
| Adam Lenkowsky | Executive VP, Chief Commercialization Officer & Head of U.S. Oncology | 0.00% |
| Karin Shanahan | Executive Vice President of Global Product Development & Supply | 0.00% |
| Robert Plenge | Executive VP, Chief Research Officer & Head of Research | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | Cari Gallman | Executive Vice President of Corporate Affairs | Derivative Exercise and Sale | -2,332 | $61.15 |
| 2026-10-01 | Cari Gallman | Executive Vice President of Corporate Affairs | Derivative Exercise and Retained | +2,227 | -- |
| 2026-09-29 | Derica Rice | Independent Director | Other Derivative Acquisition | +620 | -- |
| 2026-09-29 | Phyllis Yale | Independent Director | Other Derivative Acquisition | +560 | -- |
| 2026-09-29 | Peter Arduini | Independent Director | Other Derivative Acquisition | +560 | -- |
| 2026-09-29 | Theodore Samuels | Lead Independent Director | Other Derivative Acquisition | +821 | -- |
| 2026-09-29 | Michael McMullen | Independent director | Other Derivative Acquisition | +560 | -- |
| 2026-09-08 | Cristian Massacesi | Executive VP, Chief Medical Officer & Head of Development | Open Market Disposition | -6,249 | $64.57 |
| 2026-08-31 | Wendy Bartie | Former Senior VP & Chief of Staff to the CEO | Derivative Exercise and Sale | -633 | $66.92 |
| 2026-08-31 | Wendy Bartie | Former Senior VP & Chief of Staff to the CEO | Derivative Exercise and Retained | +603 | $66.92 |
| 2026-08-24 | Phil Holzer | Senior Vice President | Open Market Disposition | -500 | $67.50 |
| 2026-07-31 | Cristian Massacesi | Executive VP, Chief Medical Officer & Head of Development | Derivative Exercise and Sale | -26,175 | $65.31 |
| 2026-07-31 | Cristian Massacesi | Executive VP, Chief Medical Officer & Head of Development | Derivative Exercise and Retained | +24,997 | -- |
| 2026-07-31 | Cari Gallman | Executive Vice President of Corporate Affairs | Derivative Exercise and Sale | -543 | $65.31 |
| 2026-07-31 | Cari Gallman | Executive Vice President of Corporate Affairs | Derivative Exercise and Retained | +518 | -- |
| 2026-06-29 | Derica Rice | Independent Director | Other Derivative Acquisition | +672 | -- |
| 2026-06-29 | Phyllis Yale | Independent Director | Other Derivative Acquisition | +607 | -- |
| 2026-06-29 | Peter Arduini | Independent Director | Other Derivative Acquisition | +607 | -- |
| 2026-06-29 | Theodore Samuels | Lead Independent Director | Other Derivative Acquisition | +889 | -- |
| 2026-06-29 | Michael McMullen | Independent director | Other Derivative Acquisition | +607 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-16 11:00:08 · For reference only, not investment advice and not tailored to your situation.
Bristol-Myers Squibb discussion 0 comments